UNCY
Unicycive Therapeutics, Inc. (NASDAQ)
Healthcare — Biotechnology
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.
Price History
Fundamentals
| Market Cap | $149.54M |
| P/E Ratio (TTM) | - |
| Forward P/E | 1.06 |
| EPS (TTM) | $-2.25 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -163.14% |
| Debt/Equity | 2.16 |
| Recommendation | Strong Buy 1.2 |
| Analyst Target | $40.66 |
| Analysts | 9 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 36.0 |
| Beta | 1.73 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $8.74 |
| 52-Week Low | $3.71 |
| 50-Day Avg | $7.47 |
| 200-Day Avg | $6.26 |
| Avg Volume | $1.32M |
| Volume | 395.7K |
Performance Analysis
NEUTRALUNCY presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:35 UTC
Back to Screener Export Report